Glutathione S-transferase genotype is associated with sensitivity to psoralen-ultraviolet A photochemotherapy

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 380-388

  Ibbotson, S H ^a   Dawe, R S ^a   Dinkova Kostova, A T ^a   Weidlich, S ^a   Farr, P M ^b   Ferguson, J ^a   Wolf, C R ^a   Smith, G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; METHOXSALEN;

ADULT; AGED; ALLELE; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL PROTECTION; DRUG DOSE INCREASE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAMMAL CELL; OUTCOME ASSESSMENT; PHOTOCHEMOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; PUVA; RADIOSENSITIVITY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; FEMALE; GENE EXPRESSION; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; METHOXSALEN; MIDDLE AGED; OXIDATIVE STRESS; PHOTOSENSITIVITY DISORDERS; PHOTOSENSITIZING AGENTS; POLYMORPHISM, GENETIC; PSORIASIS; PUVA THERAPY; RECURRENCE; RESPONSE ELEMENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862800721     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10661.x     Document Type: Article

References (53)

1. Norris PG, Hawk JLM, Baker C, et al. British Photodermatology Group Guidelines for PUVA. Br J Dermatol 1994; 130: 246-55.
2. Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-17.
3. Collins P, Wainwright NJ, Amorim I, et al. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol 1996; 135: 248-54.
4. Buckley DA, Healy E, Rogers S,. A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis. Br J Dermatol 1995; 133: 417-22.
5. Cox NH, Farr PM, Diffey BL,. A comparison of the dose-response relationship for psoralen-UVA erythema and UVB erythema. Arch Dermatol 1989; 125: 1653-7.
6. Stern RS, Momtaz K,. Skin typing for assessment of skin-cancer risk and acute response to UV-B and oral methoxsalen photochemotherapy. Arch Dermatol 1984; 120: 869-73.
7. Sakuntabhai A, Matthews JNS, Farr PM,. Improved prediction of the minimal phototoxic dose in PUVA therapy. Br J Dermatol 1994; 130: 604-9.
8. Gordon PM, Diffey BL, Matthews JNS, et al. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999; 41: 728-32.
9. Sakuntabhai A, Sharpe GR, Farr PM,. Response of psoriasis to twice weekly PUVA. Br J Dermatol 1993; 128: 166-71.
10. Sakuntabhai A, Farr PM, Diffey BL,. PUVA erythemal sensitivity depends on plasma psoralen concentration and UVA sensitivity. Br J Dermatol 1993; 128: 561-5.
11. Marrakchi S, Decloquement L, Pollet P, et al. Variation in 8-methoxypsoralen profiles during long-term psoralen plus ultraviolet-A therapy and correlations between serum 8-methoxypsoralen levels and chromametric parameters. Photodermatol Photoimmunol Photomed 1991; 8: 206-11.
12. Ljunggren B, Bjellerup M, Carter DM,. Dose-response relations in photo-toxicity due to 8-methoxypsoralen and UV-A in man. J Invest Dermatol 1981; 76: 73-5.
13. McLelland J, Fisher C, Farr PM, et al. The relationship between plasma psoralen concentration and psoralen UVA erythema. Br J Dermatol 1991; 124: 585-90.
14. Goldstein DP, Carter DM, Ljunggren B, et al. Minimal photo-toxic doses and 8-MOP plasma levels in PUVA patients. J Invest Dermatol 1982; 78: 429-33.
15. Ibbotson SH, Dawe RS, Farr PM,. The effect of methoxsalen dose on ultraviolet-A-induced erythema. J Invest Dermatol 2001; 116: 813-15.
16. Brickl R, Schmid J, Koss FW,. Clinical pharmacology of oral psoralen drugs. Photodermatology 1984; 1: 174-86.
17. Fouin-Fortunet H, Tinel M, Descatoire V, et al. Inactivation of cytochrome-P-450 by the drug methoxsalen. J Pharmacol Exp Ther 1986; 236: 237-47.
18. Koenigs LL, Peter RM, Thompson SJ, et al. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 1997; 25: 1407-15.
19. Koenigs LL, Trager WF,. Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry (Mosc) 1998; 37: 13184-93.
20. Tantcheva-Poor I, Servera-Llanras M, Scharffetter-Kochanek K, et al. Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by PUVA in dermatology patients. Br J Dermatol 2001; 144: 1127-32.
21. Hayes JD, Flanagan JU, Jowsey IR,. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51-88.
22. Nebert DW, Vasiliou V,. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics 2004; 1: 460-4.
23. Hayes JD, Strange RC,. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154-66.
24. Dusinska M, Ficek A, Horska A, et al. Glutathione S-transferase polymorphisms influence the level of oxidative DNA damage and antioxidant protection in humans. Mutat Res 2001; 482: 47-55.
25. Wheeler LA, Aswad A, Connor MJ, et al. Depletion of cutaneous glutathione and the induction of inflammation by 8-methoxypsoralen plus UVA radiation. J Invest Dermatol 1986; 87: 658-62.
26. Smith G, Dawe RS, Clark C, et al. Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. J Invest Dermatol 2003; 121: 390-8.
27. Wolf CR, Smith G,. Pharmacogenetics. Br Med Bull 1999; 55: 366-86.
28. Seidegard J, Vorachek WR, Pero RW, et al. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293-7.
29. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione-S- transferase-theta (GSTT1): cDNA cloning and the characterization of a genetic-polymorphism. Biochem J 1994; 300: 271-6.
30. Kerb R, Brockmoller J, Reum T, et al. Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivity. J Invest Dermatol 1997; 108: 229-32.
31. Kerb R, Brockmoller J, Schlagenhaufer R, et al. Influence of GSTT1 and GSTM1 genotypes on sunburn sensitivity. Am J Pharmacogenomics 2002; 2: 147-54.
32. Smith G, Weidlich S, Dawe RS, Ibbotson SH,. Glutathione S-transferase M1 (GSTM1) genotype but not GSTT1 or MC1R genotype influences erythemal sensitivity to narrow band (TL-01) UVB phototherapy. Pharmacogenet Genomics 2011; 21: 217-24.
33. Ahmad H, Wilson DE, Fritz RR, et al. Primary and secondary structural-analyses of glutathione S-transferase-pi from human placenta. Arch Biochem Biophys 1990; 278: 398-408.
34. Ali-Osman F, Akande O, Antoun G, et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants: evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-12.
35. Laing ME, Kay E, Conlon P, et al. Genetic factors associated with skin cancer in renal transplant patients. Photodermatol Photoimmunol Photomed 2007; 23: 62-7.
36. Lear JT, Smith AG, Strange RC, et al. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br J Dermatol 2000; 142: 8-15.
37. Leite JL, Morari EC, Granja F, et al. Influence of the glutathione S-transferase gene polymorphisms on the susceptibility to basal cell skin carcinoma. Rev Med Chil 2007; 135: 301-6.
38. Lira MG, Provezza L, Malerba G, et al. Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Exp Dermatol 2006; 15: 958-65.
39. Nijsten TEC,. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252-8.
40. Lever LR, Farr PM,. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131: 215-19.
41. Moss C, Friedmann PS, Shuster S,. Impaired contact hypersensitivity in untreated psoriasis and the effects of photochemotherapy and dithranol/UV-B. Br J Dermatol 1981; 105: 503-16.
42. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer-a large-scale epidemiologic study. Lancet 1991; 338: 91-3.
43. Man I, Dawe RS, Ferguson J, et al. An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. Photochem Photobiol 2003; 78: 55-60.
44. Cameron H, Dawe RS, Yule S, et al. A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002; 147: 973-8.
45. Gasparro FP, Battista J, Song J, et al. Rapid and sensitive analysis of 8-methoxypsoralen in plasma. J Invest Dermatol 1988; 90: 234-6.
46. Prochaska HJ, Santamaria AB,. Direct measurement of NAD(P)H-quinone- reductase from cells cultured in microtiter wells-a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 1988; 169: 328-36.
47. Wang XJ, Hayes JD, Wolf CR,. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of Nrf2 by cancer chemotherapeutic agents. Cancer Res 2006; 66: 10983-94.
48. Honigsmann H, Jaschke E, Nitsche V, et al. Serum levels of 8-methoxypsoralen in two different drug preparations-correlation with photosensitivity and UV-A dose requirements for photochemotherapy. J Invest Dermatol 1982; 79: 233-6.
49. Hayes JD, McMahon M, Chowdhury S, et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2-pathway. Antioxid Redox Signal 2010; 13: 1713-48.
50. Spencer SR, Xue L, Klenz EM, et al. The potency of inducers of NAD(P)H-(quinone-acceptor) oxidoreductase parallels their efficiency as substrates for glutathione transferases-structural and electronic correlations. Biochem J 1991; 273: 711-17.
51. Talalay P, Delong MJ, Prochaska HJ,. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Acad Sci USA 1988; 85: 8261-5.
52. Dinkova-Kostova AT, Abeygunawardana C, Talalay P,. Chemoprotective properties of phenylpropenoids, bis(benzylidene)cycloalkanones, and related Michael reaction acceptors: correlation of potencies as phase 2 enzyme inducers and radical scavengers. J Med Chem 1998; 41: 5287-96.
53. Gasper AV, Al-Janobi A, Smith JA, et al. Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli. Am J Clin Nutr 2005; 82: 1283-91.